EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015

  • ID: 3308769
  • Report
  • June 2015
  • 111 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Alchemia Limited
  • Aphios Corporation
  • Helix BioMedix, Inc.
  • Lytix Biopharma AS
  • Microbiotix, Inc.
  • Oragenics, Inc.
  • MORE
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015

Summary

This, ‘Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1 2015’, provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus Faecium Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vancomycin-Resistant Enterococcus Faecium Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alchemia Limited
  • Aphios Corporation
  • Helix BioMedix, Inc.
  • Lytix Biopharma AS
  • Microbiotix, Inc.
  • Oragenics, Inc.
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Vancomycin-Resistant Enterococcus Faecium Infections Overview
Therapeutics Development
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Overview
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Development by Companies
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Development by Companies
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes
Vancomycin-Resistant Enterococcus Faecium Infections - Companies Involved in Therapeutics Development
Alchemia Limited
Alvogen, Inc.
Aphios Corporation
Cellceutix Corporation
Enanta Pharmaceuticals, Inc.
Helix BioMedix, Inc.
LegoChem Biosciences, Inc
Lytix Biopharma AS
MGB Biopharma Limited
Microbiotix, Inc.
MicuRx Pharmaceuticals, Inc.
Nabriva Therapeutics AG
NovaBay Pharmaceuticals, Inc.
NovoBiotic Pharmaceuticals, LLC
Oragenics, Inc.
Sealife PHARMA GMBH
Sentinella Pharmaceuticals, Inc.
TAXIS Pharmaceuticals, Inc.
Wockhardt Limited
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
auriclosene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brilacidin tetrahydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chrysophaentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
closthioamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EDP-788 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epimerox - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HB-1345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HT-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HT-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBN-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCB-010371 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LCB-010699 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lefamulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LTX-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Marinus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBX-1162 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MU-1140 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAI-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAI-603 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-2078 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Teixobactin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TXA-709 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WCK-4086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vancomycin-Resistant Enterococcus Faecium Infections - Recent Pipeline Updates
– Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects
Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects
Vancomycin-Resistant Enterococcus Faecium Infections - Discontinued Products
Vancomycin-Resistant Enterococcus Faecium Infections - Product Development Milestones
Featured News & Press Releases
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H1 2015
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Alchemia Limited, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Alvogen, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Aphios Corporation, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Cellceutix Corporation, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Enanta Pharmaceuticals, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Helix BioMedix, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Lytix Biopharma AS, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by MGB Biopharma Limited, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Microbiotix, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Nabriva Therapeutics AG, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Oragenics, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Sealife PHARMA GMBH, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Wockhardt Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Recent Pipeline Updates, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects, H1 2015
Vancomycin-Resistant Enterococcus Faecium Infections - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H1 2015
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Alchemia Limited
Alvogen, Inc.
Aphios Corporation
Cellceutix Corporation
Enanta Pharmaceuticals, Inc.
Helix BioMedix, Inc.
LegoChem Biosciences, Inc
Lytix Biopharma AS
MGB Biopharma Limited
Microbiotix, Inc.
MicuRx Pharmaceuticals, Inc.
Nabriva Therapeutics AG
NovaBay Pharmaceuticals, Inc.
NovoBiotic Pharmaceuticals, LLC
Oragenics, Inc.
Sealife PHARMA GMBH
Sentinella Pharmaceuticals, Inc.
TAXIS Pharmaceuticals, Inc.
Wockhardt Limited
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll